Immune reconstitution inflammatory syndrome among HIV-infected South African infants initiating antiretroviral therapy

AIDS

Volumn 23, Issue 9, 2009, Pages 1097-1107

  Smith, Kelly ^a   Kuhn, Louise ^b   Coovadia, Ashraf ^c   Meyers, Tammy ^d   Hu, Chih Chi ^b   Reitz, Cordula ^b   Barry, Gillian ^c   Strehlau, Renate ^c   Sherman, Gayle ^e   Abrams, Elaine J ^a,b  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^b Mailman School of Public Health   (United States)

^c Empilweni Clinic   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Immune reconstitution inflammatory syndrome; Pediatric HAART; Pediatric HIV

Indexed keywords

BCG VACCINE; ETHIONAMIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; RITONAVIR; STAVUDINE; VIRUS RNA;

ABSCESS; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFANT; INJECTION SITE REACTION; LYMPHADENITIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOBACTERIUM TUBERCULOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SEBORRHEIC DERMATITIS; STREPTOCOCCUS PNEUMONIA; TREATMENT OUTCOME; TUBERCULOSIS; VIRUS PNEUMONIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BCG VACCINE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFANT; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; VIRAL LOAD;

EID: 67651083739     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832afefc     Document Type: Article

References (36)

1. Murdoch DM, Venter DF, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601-610.
2. Kumarasamy N, Chaguturu S, Mayer KH, Solomon S, Yepthomi T, Balakrishnan P, Flanigan TP. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Sydr 2004; 37:1574-1576.
3. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
4. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341.
5. Shelburne SA, Montes M, Hammill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167-170.
6. Puthanakit T, Oberdorger P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2006; 25:53-58.
7. Zampoli M, Kilborn T, Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis 2007; 11:417-423.
8. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
9. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
10. Battegay M, Nuesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006; 6:280-287.
11. Jevtovic DJ, Salemovic D, Ranin J, Pesic I, Zerjav S, Djurkovic-Djakovi O. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2005; 6:140-143.
12. World Health Organization. Towards universal access: scaling up priority interventions in the health sector. Progress Report. WHO, Geneva, June 2008. http://www.who.int/hiv/pub/towards-universal-access-report-2008.pdf [Accessed March 16, 2009]
13. UNAIDS. Children and AIDS. Second stocktaking report. Actions and Progress 2008. http://data.unaids.org/pub/Report/2008/ childrenandaidssecondstocktakingreport-en.pdf [Accessed March 16, 2009]
14. Rabie H, Violari A, Madhi S, Gibb DM, Stayn J, Van Niekerk R, et al. Complications of BCG vaccination in HIV infected and uninfected children: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) study. 14th Conference on Retroviruses and Opportunistic Infections. Boston, Mass 2008. Abstract 600. http://www.retroconference.org/ 2008/Abstracts/33235.htm. [Accessed March 16, 2009]
15. Boerma JT, Stanecki KA, Newell ML, Luo C, Beusenberg M, Garnett GP, et al. Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. Bull World Health Organ 2006; 84:145-160.
16. Puthanakit T, Oberdorfer P, Punjaisee S, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome due to Bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41:1049-1052.
17. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, et al. Bacille Calmette-Guérin (BCG) vaccine induced disease in HIV-infected and uninfected children. Clin Infect Dis 2006; 42:548-558.
18. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, Godfrey-Faussett P, et al. The risk of disseminated Bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-18.
19. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access: recommendations for a public health approach. Geneva, September 2006. http://www.who.int/hiv/pub/guidelines/paediatric020907.pdf. [Accessed 16 March 2009]
20. South Africa Department of Health. Guidelines for the management of HIV-infected children, 2005. http://www.doh.gov.za/docs/policy-f.html. [Accessed January 2009]
21. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith JP, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 15:566-569.
22. Marais BJ, Graham SM, Cotton MF, Beyers M. Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis 2007; 196 (Suppl 1):S76-95.
23. World Health Organization. WHO Anthro (version 2) and macros. http://who.int/childgrowth/software/en/2005. [Accessed 16 March 2009].
24. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
25. World Health Organization. Safety of BCG vaccine in HIV-infected children. Wkly Epidemiol Rec 2007; 82:17-24. http://www.who.int/wer. [Accessed 16 March 2009]
26. World Health Orgnaization. Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting. Geneva, Switzerland 2008. http://www.who.int/hiv/pub/paediatric/WHO-Paediatric-ART-guideline-rev- mreport-2008.pdf. [Accessed 16 March 2009]
27. Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, Van Dyke R, et al. Long-term effects of long term antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008; 46:1751-1760.
28. Kovacs A, Montepiedra G, Carey V, Pahwa S, Weinberg A, Frenkel L, et al. Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response. J Infec Dis 2005; 192:296-302.
29. Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008; 22:249-255.
30. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, et al. Early virologic suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 2008; 22:1333-1343.
31. La Porte CJ CE, Bertz R. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-1560.
32. Ren Y, Nuttall J, Egbers C, Eley B, Meyers T, Maartens G, et al. Plasma concentrations of efavirenz and lopinavir in children with and without rifampicin-based anti-TB treatment. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California Abstract #77, 2007.
33. Chadwick EG, Rodman JH, Britto P, Powell C, Palumbo P, Luzuriaga K, et al. Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age. Pediatr Infect Dis J 2005; 24:793-800.
34. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Paediatric tuberculosis. Lancet 2008; 8:498-510.
35. Ribera E, Azuaja C, Lopez RM, Domingo P, Curran A, Feijoo M, et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 2007; 59:690-697.
36. Davies MA, Boulle A, Fakir T, Nuttall J, Eley B. Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatr 2008; 8:34.